Although the history of cancer treatment has many success stories, cancer remains an immense source of human suffering. The genomic revolution provides an unprecedented opportunity to revolutionize cancer treatment, however our current approaches cannot fully capitalize on the latest scientific discoveries. Conventional clinical trials ignore the fundamental lesson of genomics - that every cancer is different. To fully realize the transformational potential of this technological revolution we must completely restructure our approach to evaluating and treating cancer. Partners in Personal Oncology (PiPO) is a 501(c)(3) organization created for this purpose. Co-founded by Tony Blau and Greg Foltz, a neurosurgeon at Swedish Hospital, PiPO transcends institutional boundaries to bring best-in-the-world technology and individualized advice to the treatment of cancer patients today, while furthering our understanding of cancer for the benefit of future generations. More information can be found at www.personaloncology.org.